In the first part of a two-part series, Carre reviews of the tau and TREM2 approaches reshaping Alzheimer's drug development, with key findings from AAIC 2026 in London.
Ivo Carre
Advertisement
Ivo Carre, PhD, is a Senior Business Analyst at Lifescience Dynamics in London, with a doctorate in Neuroscience from the UKDRI and over two years of Biopharma consulting experience. He has supported various clients across several indications, including oncology, neurology and rare diseases, with expertise in competitive intelligence, market research, and market access.
Articles by Ivo Carre
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
2
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
3
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
4
When Drug Pricing Becomes Trade Policy
5